Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2018
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2018
SUMMARY
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events.
Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 13 and 10 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Melanoma, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Colorectal Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Depression, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Sclerosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lupus Nephritis, Lymphoma, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neuroblastoma, Neurodegenerative Diseases, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Thyroid Cancer and Unspecified B-Cell Lymphomas.
The latest report Histone Deacetylase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events.
Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 13 and 10 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Melanoma, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Colorectal Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Depression, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Multiple Sclerosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lupus Nephritis, Lymphoma, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neuroblastoma, Neurodegenerative Diseases, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Thyroid Cancer and Unspecified B-Cell Lymphomas.
The latest report Histone Deacetylase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Celgene Corp
Chong Kun Dang Pharmaceutical Corp
Curis Inc
HitGen LTD
Kancera AB
Karus Therapeutics Ltd
Medivir AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
OnKure Inc
Quimatryx SL
Shuttle Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
citarinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IKH-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-2507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPT-0B291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexturastat A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-259 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
Sep 27, 2017: Clinical trial reveals genetic fault that reduces the effectiveness of leukaemia treatment
Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma
Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Celgene Corp
Chong Kun Dang Pharmaceutical Corp
Curis Inc
HitGen LTD
Kancera AB
Karus Therapeutics Ltd
Medivir AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
OnKure Inc
Quimatryx SL
Shuttle Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
ACY-1083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
citarinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IKH-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-2507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-0439782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPT-0B291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexturastat A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QTX-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Charcot-Marie-Tooth Disease and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-259 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
Sep 27, 2017: Clinical trial reveals genetic fault that reduces the effectiveness of leukaemia treatment
Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma
Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting
Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by Kancera AB, H1 2018
Pipeline by Karus Therapeutics Ltd, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by OnKure Inc, H1 2018
Pipeline by Quimatryx SL, H1 2018
Pipeline by Shuttle Pharmaceuticals LLC, H1 2018
Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by Kancera AB, H1 2018
Pipeline by Karus Therapeutics Ltd, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by OnKure Inc, H1 2018
Pipeline by Quimatryx SL, H1 2018
Pipeline by Shuttle Pharmaceuticals LLC, H1 2018
Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
AlfaSigma SpA
Celgene Corp
Chong Kun Dang Pharmaceutical Corp
Curis Inc
HitGen LTD
Kancera AB
Karus Therapeutics Ltd
Medivir AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
OnKure Inc
Quimatryx SL
Shuttle Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
AlfaSigma SpA
Celgene Corp
Chong Kun Dang Pharmaceutical Corp
Curis Inc
HitGen LTD
Kancera AB
Karus Therapeutics Ltd
Medivir AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
OnKure Inc
Quimatryx SL
Shuttle Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
